Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions of two signature mutations in mice engineered to sustain pancreas-specific Cre-mediated activation of a mutant Kras allele ( Kras G12D ) and deletion of a conditional Ink4a/Arf tumor suppressor allele. The phenotypic impact of Kras G12D alone was limited primarily to the development of focal premalignant ductal lesions, termed pancreatic intraepithelial neoplasias (PanINs), whereas the sole inactivation of Ink4a/Arf failed to produce any neoplastic lesions in the pancreas. In combination, Kras G12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. The evolution of these tumors bears striking resemblance to the human disease, possessing a proliferative stromal component and ductal lesions with a propensity to advance to a poorly differentiated state. These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma. This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These KRAS mutations are also found in the early stages of pancreatic ductal adenocarcinoma, preceding the appearance of senescence markers such as p53, CDKN2A and SMAD4196.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [196]
Experimental — accuracy not yet measuredIn the citing paper
“In a mouse model, CDKN2A loss accelerated KRASG12D-driven tumor growth54.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [54]
In the citing paper
“GEMMs with compound mutations that combine Kras mutation with the inactivation of tumor suppressor genes Cdkn2a and Tp53, or with the inactivation of the TGFβ-SMAD4 signaling pathway in the pancreas develop invasive and metastatic PDAC (74–76), thus validating the role of these tumor suppressor pathways in PDAC progression (4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [74]
In the citing paper
“combined expression of oncogenic Kras coupled with the deletion or loss of function of Trp53, Cdkn2a, or Smad4 in the pancreas of mice readily leads to invasive PDAC29–32.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundSelf-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Although ARF is a known activator of the p53 pathway (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998) and its loss clearly attenuates the function of that critical tumor suppressor, more recent studies have demonstrated that ARF has p53-independent…”
BackgroundSelf-citationGu, G., Dubauskaite, J., & Melton, D. A. (2002) · Development · doi:10.1242/dev.129.10.2447 · Cited by 1,518
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Warshaw, A. L., & Castillo, C. F.-D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202133260706 · Cited by 1,198
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Research works printed but not linked: 17
- 2003, Cancer Res., 63, 2005
- 1976, Cancer Res., 36, 2690
- 1990, Mol. Cell. Biol., 10, 1779
- 1992, Am. J. Pathol., 140, 1237
- 2003, Cancer Res., 63, 2016
- 2001, Cancer Res., 61, 4923
- 1994, Am. J. Pathol., 145, 1547
- 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O · doi:10.1002/(sici)1098-2264(200004)27:4<358::aid-gcc4>3.0.co;2-o
- 10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R · DOI
- 2001, Cancer J., 7, 242
- 1997, Cancer Res., 57, 2140
- 1997, Cancer Res., 57, 1731
- 1998, Biochim. Biophys. Acta, 1378, F115
- 1998, Cancer Res., 58, 4740
- 2000, Cancer Res., 60, 2002
- 1986, Jpn. J. Cancer Res., 77, 370
- 1994, Am. J. Pathol., 145, 671
Cited by
Items 501–600 of 999
Ueda, S., Fukamachi, K., Matsuoka, Y., Takasuka, N., Takeshita, F., Naito, A., Iigo, M., Alexander, D. B., Moore, M. A., Saito, I., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl090 · Cited by 36
Nalbantoğlu, S., & Karadağ, A. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114031 · Cited by 39
Hill, K. S., Gažiová, I., Harrigal, L. J., Guerra, Y. A., Qiu, S., Sastry, S. K., Arumugam, T., Logsdon, C. D., & Elferink, L. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040420 · Cited by 33
“Examples are PanIN-1 (Kras activation, loss of Notch2) [8,9], PanIN-2 (loss of function mutations in tumor suppressor p53 and p16INK4a) [10] and PanIN-3 (inactivation of p53, SMAD4/DPC4 and BRCA2) [8,11,12].”
BackgroundBmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism
Bednar, F., Schofield, H. K., Collins, M. A., Yan, W., Zhang, Y., Shyam, N., Eberle-Singh, J. A., Almada, L. L., Olive, K. P., Bardeesy, N. M., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv058 · Cited by 37
“cancer develops advanced neoplastic lesions rapidly even in the absence of pancreatitis (1,22).”
Self-citationSamain, R., Brunel, A., Douché, T., Fanjul, M., Cassant‐Sourdy, S., Rochotte, J., Cros, J. F., Neuzillet, C., Raffenne, J., Duluc, C., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.008 · Cited by 40
“KPC, LSL-KrasG12D/þ; Ink4a; Pdx-1Creþ/-, and KOsst1mice have beendescribed previously.(18,20,45) KPC model.”
Li, Z., Gonzalez, C. L., Wang, B., Zhang, Y., Mejia, O., Katsonis, P., Lichtarge, O., Myers, J. N., El‐Naggar, A. K., & Caulín, C. (2016) · The Journal of Pathology · doi:10.1002/path.4770 · Cited by 37
“To delete the Cdkn2a gene in the skin, we crossed mice carrying a floxed Cdkn2a allele (Cdkn2af) [25] with K5.”
BackgroundGolan, T., Stossel, C., Schvimer, M., Atias, D., Halperin, S., Buzhor, E., Raitses‐Gurevich, M., Cohen, K., Pri‐Chen, S., Wilson, J. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17253 · Cited by 34
“Genetically engineered mice (GEM) with mutations in KRAS and p53 [9], SMAD4 [10] and P16/INK4 [11] have been established, however, these models frequently have incomplete penetrance, long latency periods and are limited to specific, predefined genetic mutations [12].”
BackgroundDeramaudt, T. B., Takaoka, M., Upadhyay, R., Bowser, M., Porter, J., Lee, A. S., Rhoades, B., Johnstone, C. N., Weissleder, R., Hingorani, S. R., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01055-05 · Cited by 36
“(C) Bioluminescence signals of subcutaneous tumor growth at week 4 after mice were injected with Ki-RAS/p53-luc-PDC (1) or tumor-derived cells (2).”
BackgroundMethodOmenn, G. S., Menon, R., & Zhang, Y. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.04.007 · Cited by 34
“[26] Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, et al.”
AKT regulates NPM dependent ARF localization and p53mut stability in tumors
Hamilton, G., Abraham, A., Morton, J. P., Sampson, O. L., Pefani, D., Khoronenkova, S. V., Grawenda, A. M., Papaspyropoulos, A., Jamieson, N. B., McKay, C. J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2178 · Cited by 39
“While ARF activity maybe lost due to mutations at the INK4A/ARF locus, a number of studies have shown that they can be mutually exclusive, where INK4A maybe lost while sparing ARF [33].”
BackgroundBabicky, M. L., Harper, M. M., Chakedis, J. M., Cazes, A., Mose, E. S., Jaquish, D. V., French, R. P., Childers, B. G., Alakus, H., Schmid, M. C., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0811-9 · Cited by 33
A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma
Fitzgerald, B., Connolly, K. A., Cui, C., Fagerberg, E., Mariuzza, D. L., Hornick, N. I., Foster, G. G., William, I., Cheung, J. F., & Joshi, N. S. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100080 · Cited by 40
Gan, Q., Roy‐Chowdhuri, S., Duose, D. Y., Stewart, J., Coronel, E. S., Bhutani, M. S., Lee, J. H., Weston, B. R., Ge, P. S., Ross, W. A., et al. (2021) · Cancer Cytopathology · doi:10.1002/cncy.22533 · Cited by 35
Targeting angiogenesis in pancreatic cancer: rationale and pitfalls
Whipple, C. A., & Korc, M. (2008) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-008-0280-z · Cited by 37
“Activating KRAS mutations are often the first genetic mutation to be detected which suggests an initiating role in tumorigenesis [7].”
BackgroundTrp53 Deletion Stimulates the Formation of Metastatic Pancreatic Tumors
Morton, J. P., Klimstra, D. S., Mongeau, M. E., & Lewis, B. C. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070778 · Cited by 33
Davies, C. C., Harvey, E., McMahon, R. F., Finegan, K. G., Connor, F., Davis, R. J., Tuveson, D. A., & Tournier, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2941 · Cited by 32
“strain (2, 3), these neoplastic ducts rarely progressed, with only one mouse displaying mPanIN-2 and PDAC at 9 months of age (Fig.”
BackgroundSelf-citationThe Id3/E47 Axis Mediates Cell-Cycle Control in Human Pancreatic Ducts and Adenocarcinoma
Lee, S. H., Hao, E., Kiselyuk, A., Shapiro, J., Shields, D. J., Lowy, A. M., Levine, F., & Itkin‐Ansari, P. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0535 · Cited by 35
“In contrast, mice carrying the single deletion of p16 display no pancreatic pathology (38).”
BackgroundGenetically-engineered mouse models for pancreatic cancer: Advances and current limitations
Ijichi, H. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i5.195 · Cited by 33
Pancreatic Ductal Adenocarcinoma: Cellular Origin, Signaling Pathways and Stroma Contribution
Hernńdez-Muñoz, I., Skoudy, A., Real, F. X., & Navarro, P. (2008) · Pancreatology · doi:10.1159/000151537 · Cited by 39
“Mouse models using activated K-Ras have provided further insights into the cell of origin of PDAC. These models have used knock-in strategies for conditional activation of a Kras G12D allele by Cre-loxP recombination. Pancreas-specific activation of K-Ras leads to the development of PanIN lesions [”
Hance, K. W., Zeytin, H. E., & Greiner, J. W. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.10.014 · Cited by 36
“The pancreatic adenocarcinomas progress rapidly, become highly invasive, and develop metastases that result in the death of all Pdx1-Cre;LSLKras;Ink4a/Arflox/lox mice by 11 weeks of age [73].”
BackgroundInfluentialDiscovery of cancer biomarkers through the use of mouse models
Kuick, R. D., Misek, D. E., Monsma, D. J., Webb, C. P., Wang, H., Peterson, K. J., Pisano, M. R., Omenn, G. S., & Hanash, S. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.032 · Cited by 32
Pancreatic cancer models for translational research
Behrens, D., Walther, W., & Fichtner, I. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.013 · Cited by 40
TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma
Parajuli, P., Singh, P., Wang, Z., Li, L., Eragamreddi, S., Ozkan, S., Ferrigno, O., Prunier, C., Razzaque, M. S., Xu, K., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018101067 · Cited by 30
Roger, É., Gout, J., Arnold, F., Beutel, A. K., Müller, M., Abaei, A., Barth, T. F. E., Rasche, V., Seufferlein, T. T. W., Perkhofer, L., et al. (2020) · Cells · doi:10.3390/cells9092110 · Cited by 31
“In line with previous reports from highly aggressive PDAC models [28], vehicle-treated mice died as a result of ultra-fast uncontrolled tumor growth lacking the ability of pronounced metastatic tumor dissemination.”
ResultTumor Microenvironment in Pancreatic Intraepithelial Neoplasia
Opitz, F. V., Häberle, L., Daum, A., & Esposito, I. (2021) · Cancers · doi:10.3390/cancers13246188 · Cited by 37
Feldmann, G., Karikari, C. A., Molin, M. D., Duringer, S., Volkmann, P., Bartsch, D. K., Bisht, S., Koorstra, J.-B. M., Brossart, P., Maitra, A., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.11.15534 · Cited by 34
“A putative “antagonistic” relation between Brca2 deficiency and mutant Kras is also bolstered by the observation that, in the presence of intact p53 function, the incidence of mPanINs and PDAC was actually lower compared to mice expressing mutant Kras alone, when both genes were altered in the pancreatic epithelium.39…”
BackgroundInfluentialSweating the Small Stuff: MicroRNAs and Genetic Changes Define Pancreatic Cancer
Tang, S., Bonaroti, J. W., Unlu, S., Liang, X., Tang, D., Zeh, H. J., & Lotze, M. T. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182854ab0 · Cited by 33
Deploying Mouse Models of Pancreatic Cancer for Chemoprevention Studies
Grippo, P. J., & Tuveson, D. A. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0258 · Cited by 30
Self-citationHBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss
Shin, C., Robinson, J. P., Sonnen, J. A., Welker, A., Yu, D., VanBrocklin, M. W., & Holmen, S. L. (2017) · Oncogene · doi:10.1038/onc.2017.83 · Cited by 30
Klein, C. H., Truxius, D. C., Vogel, H. A., Harizanova, J., Murarka, S., Martín‐Gago, P., & Bastiaens, P. I. H. (2018) · International Journal of Cancer · doi:10.1002/ijc.31859 · Cited by 32
Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis
Matsuura, T., Maru, Y., Izumiya, M., Hoshi, D., Kato, S., Ochiai, M., Hori, M., Yamamoto, S., Tatsuno, K., Imai, T., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz122 · Cited by 30
Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells
Chang, Z., Li, Z., Wang, X., Kang, Y., Yuan, Y., Niu, J., Wang, H., Chatterjee, D., Fleming, J. B., Li, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0032 · Cited by 31
Acinar Cell Reprogramming: A Clinically Important Target in Pancreatic Disease
Pin, C. L., Ryan, J. F., & Mehmood, R. (2015) · Epigenomics · doi:10.2217/epi.14.83 · Cited by 33
Pancreatic Cancer and Hedgehog Pathway Signaling: New Insights
Dosch, J. S., di Magliano, M. P., & Simeone, D. M. (2010) · Pancreatology · doi:10.1159/000225923 · Cited by 32
Pancreatic Schwann cell reprogramming supports cancer‐associated neuronal remodeling
Rangel‐Sosa, M. M., Mann, F., & Chauvet, S. (2024) · Glia · doi:10.1002/glia.24586 · Cited by 34
“KIC mutant mice ( Kras LSL-G12D/ + ; Cdkn2a ( Ink4a/Arf ) lox/lox ; Pdx1-Cre ) were generated in-house by intercrossing Kras LSL-G12D/ + (Jackson et al., 2001), Pdx1-Cre Cre (G. Gu et al., 2002), and Cdkn2a lox/lox (Aguirre et al., 2003) mice.”
Hydrogel Models with Stiffness Gradients for Interrogating Pancreatic Cancer Cell Fate
Chang, C., & Lin, C. (2021) · Bioengineering · doi:10.3390/bioengineering8030037 · Cited by 31
“found that the combination of KrasG12D activation and Ink4a/Arf suppression resulted in the early development of PanIN, which readily progressed to highly invasive and metastatic cancers [57].”
BackgroundRacu, M.-L., Lebrun, L., Schiavo, A. A., Campenhout, C. V., Clercq, S. D., Absil, L., Minguijón, E., Maris, C., Decaestecker, C., Salmon, I. J., et al. (2022) · Cancers · doi:10.3390/cancers14040973 · Cited by 36
Garcia, P. L., Christein, J. D., Arnoletti, J. P., Heslin, M. J., Gamblin, T. L., Richardson, J. H., Bjornsti, M., & Yoon, K. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078183 · Cited by 30
Baumgart, M., Werther, M., Bockholt, A., Scheurer, M., Rüschoff, J., Dietmaier, W., Ghadimi, B. M., & Heinmöller, E. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181dc62f6 · Cited by 29
Majeti, B. K., Lee, J. H., Simmons, B. H., & Shojaei, F. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-213 · Cited by 30
“Mutations in the KRAS gene lead to KRas protein activation in many human tumors including NSCLC, pancreatic cancer and colorectal cancer [12-14].”
BackgroundChanges in Connexin43 Expression and Localization During Pancreatic Cancer Progression
Solan, J. L., Hingorani, S. R., & Lampe, P. D. (2012) · The Journal of Membrane Biology · doi:10.1007/s00232-012-9446-2 · Cited by 31
“Animal models of preinvasive and invasive PDA (Aguirre et al. 2003; Hingorani et al. 2003, 2005) have been generated through the targeted physiologic expression of oncogenic Kras to the mouse pancreas (hereafter termed K* mouse).”
Oncolytic virotherapy for pancreatic cancer
Wennier, S. T., Li, S., & McFadden, G. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001876 · Cited by 29
The renewed battle against RAS-mutant cancers
Zhang, F., & Cheong, J. K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2155-8 · Cited by 32
Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development
Chen, C., Chen, L.-L., Li, C., Hsu, Y.-T., Jiang, S. S., Fan, C.-S., Chua, K. V., Huang, S., Shyr, Y., Chen, L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424612 · Cited by 30
Molecular Pathology of Pancreatic Cancer: Implications for Molecular Targeting Therapy
Furukawa, T. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.035 · Cited by 33
Pancreatic cancer stem cell biology and its therapeutic implications
Bednar, F., & Simeone, D. M. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-011-0494-7 · Cited by 27
“Over the past decade new mouse models of pancreatic cancer have been described that recapitulate the pathology of the human disease [30–32].”
BackgroundPancreatic Intraepithelial Neoplasia
Cornish, T. C., & Hruban, R. H. (2011) · Surgical pathology clinics · doi:10.1016/j.path.2011.03.005 · Cited by 32
Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze
Olivares, O., & Vasseur, S. (2015) · International Journal of Cancer · doi:10.1002/ijc.29501 · Cited by 29
Non-canonical functions of SNAIL drive context-specific cancer progression
Paul, M. C., Schneeweis, C., Falcomatà, C., Shan, C., Rossmeisl, D., Koutsouli, S., Klement, C., Zukowska, M., Widholz, S. A., Jesinghaus, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36505-0 · Cited by 34
Senescence in pancreatic carcinogenesis: from signalling to chromatin remodelling and epigenetics
Singh, S. K., & Ellenrieder, V. (2013) · Gut · doi:10.1136/gutjnl-2012-302793 · Cited by 28
In vitromodels of pancreatic cancer for translational oncology research
Feldmann, G., Rauenzahn, S. L., & Maitra, A. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440902821657 · Cited by 28
“In yet another example, DePinho and colleagues reported that pancreas-specific targeting of oncogenic KrasG12D expression in combination with abrogated Ink4a/Arf (murine p16 and p19) function by crossing on a Pdx1-Cre genetic background led to the rapid formation of poorly differentiated pancreatic cancers [102].”
BackgroundLin, K. Y., Maricevich, M., Bardeesy, N. M., Weissleder, R., & Mahmood, U. (2008) · Translational Oncology · doi:10.1593/tlo.08118 · Cited by 30
“Both NB587 and NB743 primary cell lines gave rise to these findings, and these features were also consistent with those previously reported by investigators using the same primary cell lines [12].”
BackgroundMethodResultInfluentialSelf-citationDodd, R. D., Lee, C., Overton, T., Huang, W., Eward, W. C., Luo, L., Ma, Y., Ingram, D. R., Torres, K. E., Cardona, D. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2643 · Cited by 32
Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells
Deng, X., & Friedman, E. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.29 · Cited by 30
“Pdx-1-cre LSL/KrasG12D/Ink4a/Arf null mice were bred, genotyped at weaning, then either treated with EHT5372 alone or left untreated for eight weeks when all mice should show tumor growth [34], or until death or sacrifice because of ill health.”
BackgroundMethodMajumder, K., Arora, N., Modi, S., Chugh, R., Nomura, A., Giri, B., Dawra, R. K., Ramakrishnan, S., Banerjee, S., Saluja, A. K., et al. (2015) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-015-2985-y · Cited by 30
“,(8) a number of mouse models with a combination of mutant Kras and other targeted mutations such as Ink4a/Arf andMUC1 have been used to study the pathogenesis and progression of pancreatic cancer.(21) –23 Genetically engineered KPC mice have an overall median survival of 5.”
Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma
Ferguson, L. P., Gatchalian, J., McDermott, M. L., Nakamura, M., Chambers, K. R., Rajbhandari, N., Lytle, N. K., Rosenthal, S. B., Hamilton, M., Albini, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35796-7 · Cited by 29
Sempere, L. F., & Korc, M. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-287-2_4 · Cited by 30
The Genetic Basis of Sporadic Pancreatic Cancer
Baumgart, M., Heinmöller, E., Horstmann, O., Becker, H., & Ghadimi, Β. M. (2005) · Analytical Cellular Pathology · doi:10.1155/2005/632939 · Cited by 34
“Especially new animal models that allow the development of premalignant lesions are believed to improve early detection methods [1,35,47].”
BackgroundLiao, D. J., Wang, Y., Wu, J., Adsay, V. N., Grignon, D. J., Khanani, F., & Sarkar, F. H. (2006) · Journal of Carcinogenesis · doi:10.1186/1477-3163-5-19 · Cited by 27
“Most of the currently existing transgenic mouse models of pancreatic carcinogenesis produce only acinar-ductal metaplasia and ductal proliferation, with zero or very low penetrance of developing frank pancreatic tumors, unless the transgenic mice are concomitantly deficient in certain tumor suppressor genes such as In…”
InfluentialDisputed Paternity: The Uncertain Ancestry of Pancreatic Ductal Neoplasia
Maitra, A., & Leach, S. D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.11.015 · Cited by 29
“Initial seminal work in this arena utilized either Pdx1Cre or Ptf1aCre alleles to activate Kras in embryonic pancreatic progenitor cells (Aguirre et al., 2003; Hingorani et al., 2003).”
BackgroundMammalian Interphase Cdks: Dispensable Master Regulators of the Cell Cycle
Enders, G. H. (2012) · Genes & Cancer · doi:10.1177/1947601913479799 · Cited by 30
The molecular biology of pancreatic cancer.
Abramson, M. A., Jazag, A., van der Zee, J. A., & Whang, E. E. (2007) · PubMed · Cited by 31
Godfrey, J. D., Morton, J. P., Wilczynska, A., Sansom, O. J., & Bushell, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0628-4 · Cited by 29
Schulz, P. M., Scholz, A., Rexin, A., Hauff, P., Schirner, M., Wiedenmann, B., & Detjen, K. M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604457 · Cited by 27
“…the analysis of clinical specimens and corroborated by subsequent genetic studies in mice, as tissue-specific oncogenic activation of K-ras in Ink4a/ARF / or Ink4A / /ARF þ /þ mice, but not in wild-type mice resulted in pancreatic ductal adenocarcinoma (Aguirre et al, 2003; Bardeesy et al, 2006).”
BackgroundThe molecular pathogenesis of pancreatic cancer: clarifying a complex circuitryPreprint
Rustgi, A. K. (2006) · Genes & Development · doi:10.1101/gad.1501106 · Cited by 27
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Long, S.-A., Amparo, A. M., Goodhart, G., Ahmad, S. A., & Waters, A. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402128 · Cited by 31
Biomarkers and the genetics of early neoplastic lesions
Srivastava, S., & Grizzle, W. E. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0204 · Cited by 27
“, pancreatic cancer) also may be useful in identifying molecular features leading to the development of metastatic disease (15,16).”
Molecular biology of pancreatic cancer
Belda-Iniesta, C., de Cáceres, I. I., Barriuso, J., de Castro, J., Barón, M. G., & Feliú, J. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0247-6 · Cited by 27
Driver mutations: A roadmap for getting close and personal in pancreatic cancer
Korc, M. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.6.13128 · Cited by 31
“Aurora A PI3Ks has a Ras binding site, and activation of either the IA or IB subclass leads to the generation of phosphatidylinositol (3,4,5)-trisphosphate (PIP 3 ) from phosphatidylinositol (4,5)-bisphosphate (PIP 2 ).”
BackgroundMirus, J. E., Zhang, Y., Hollingsworth, M. A., Solan, J. L., Lampe, P. D., & Hingorani, S. R. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.036517 · Cited by 28
“well as the relative timing of these events (8, 10, 11).”
BackgroundBeilke, S., Oswald, F., Genze, F., Wirth, T. C., Adler, G., & Wagner, M. (2010) · Oncogene · doi:10.1038/onc.2010.156 · Cited by 26
Molecular changes in pancreatic cancer
Buchholz, M., & Gress, T. M. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.107 · Cited by 28
A mouse plasma peptide atlas as a resource for disease proteomics
Zhang, Q. H., Menon, R., Deutsch, E. W., Pitteri, S. J., Faça, V. M., Wang, H., Newcomb, L. F., DePinho, R. A., Bardeesy, N. M., Dinulescu, D. M., et al. (2008) · Genome biology · doi:10.1186/gb-2008-9-6-r93 · Cited by 27
“Pancreatic cancer and matched control 347 [42] Kras and INK/ARF FVB/n 163 Thermo LTQ-FT”
Self-citationSato, K., Hikita, H., Myojin, Y., Fukumoto, K., Murai, K., Sakane, S., Tamura, T., Yamai, T., Nozaki, Y., Yoshioka, T., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235573 · Cited by 29
Mouse models of K-ras-initiated carcinogenesis
Janssen, K., Abala, M., Marjou, F. E., Louvard, D., & Robine, S. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.07.004 · Cited by 35
Molecular imaging in pancreatic cancer – A roadmap for therapeutic decisions
Krämer-Marek, G., Gore, J., & Korc, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.008 · Cited by 26
“By contrast, combining oncogenic Kras with inactivation of tumor suppressor genes, such as Ink4a, p53 and SMAD4 markedly accelerated PanIN progression to mPDAC [30-32].”
Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?
Holly, J. M. P., Zeng, L., & Perks, C. M. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9445-5 · Cited by 31
“Mutations in KRAS2 can initiate the development of pancreatic cancer [40] but the same mutations may result in hyperplasia in the colon [41] or borderline lesions that do not progress to carcinomas in the ovary [42].”
BackgroundA historical perspective of pancreatic cancer mouse models
Colvin, E. K., & Scarlett, C. J. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.03.025 · Cited by 28
Ghurburrun, E., Borbath, I., Lemaigre, F. P., & Jacquemin, P. (2018) · Gene Expression · doi:10.3727/105221618x15216414278706 · Cited by 26
Tsutaho, A., Hashimoto, A., Hashimoto, S., Hata, S., Kachi, S., Hirano, S., & Sabe, H. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00608-8 · Cited by 29
Identifying modules of cooperating cancer drivers
Klein, M., Cannataro, V. L., Townsend, J. P., Newman, S., Stern, D. F., & Zhao, H. (2021) · Molecular Systems Biology · doi:10.15252/msb.20209810 · Cited by 26
“Evidence in multiple cancer types supports the cooperation between activating mutations in KRAS and loss of the G1/S checkpoint by inactivation of CDKN2A or TP53 [7, 8, 9].”
BackgroundRNAi-Based Approaches for Pancreatic Cancer Therapy
Kim, M. J., Chang, H., Nam, G., Ko, Y., Kim, S. H., Roberts, T. M., & Ryu, J. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101638 · Cited by 25
“When coupled with mutational inactivation of TP53 (TP53R175H), CDKN2A, or SMAD4, pancreatic intraepithelial neoplasia formation rapidly evolves into high-frequency occurrence of metastatic PDAC [41,43,44].”
BackgroundRAS‐targeted cancer therapy: Advances in drugging specific mutations
Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 30
Appleman, V. A., Ahronian, L. G., Cai, J., Klimstra, D. S., & Lewis, B. C. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0340-t · Cited by 32
Molecular biology of pancreatic cancer--new aspects and targets.
Schneider, G., Hamacher, R., Eser, S., Frieß, H., Schmid, R. M., & Saur, D. (2008) · PubMed · Cited by 34
B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma
Minici, C., Testoni, S. G. G., & Della‐Torre, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867902 · Cited by 24
DEMOC: a deep embedded multi-omics learning approach for clustering single-cell CITE-seq data
Zou, G., Lin, Y., Han, T., & Ou-Yang, L. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac347 · Cited by 25
Mouse models of Kras activation in gastric cancer
Won, Y., & Choi, E.-Y. K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00882-1 · Cited by 28
Faro, A., Boj, S. F., & Clevers, H. C. (2009) · Zebrafish · doi:10.1089/zeb.2009.0617 · Cited by 27
Honig, G., Liou, A., Berger, M., German, M. S., & Tecott, L. H. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-82 · Cited by 24
Loss of Pancreatic E-Cadherin Causes Pancreatitis-Like Changes and Contributes to Carcinogenesis
Kaneta, Y., Sato, T. A., Hikiba, Y., Sugimori, M., Sue, S., Kaneko, H., Irie, K., Sasaki, T., Kondo, M., Chuma, M., et al. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.09.001 · Cited by 25
Transgenic Mouse Models—A Seminal Breakthrough in Oncogene Research
Smith, H. W., & Muller, W. J. (2013) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069765 · Cited by 26
“pancreas, including Pdx1, p48, and Mist-1 (Aguirre et al. 2003; Hingorani et al. 2003, 2005; Tuveson et al. 2006).”
Wang, C., Hou, Y., Hong, Y., Tai, †. Y.-H., Shen, C., Hou, P., Fu, J.-L., Wu, C.-L., Cheng, S. M., Hwang, D., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02207-4 · Cited by 26
Advances in the Genetics and Biology of Pancreatic Cancer
Aguirre, A. J., & Collisson, E. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000286 · Cited by 25
Self-citationLangdon, C. G., Gadek, K. E., Garcia, M. R., Evans, M. K., Reed, K. B., Bush, M., Hanna, J. A., Drummond, C. J., Maguire, M. C., Leavey, P. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25829-4 · Cited by 26
Seavey, C. N., Hallett, A., Li, S., Che, K., Pobbati, A. V., Ma, S., Burtscher, A., Kanai, R., Lamar, J. M., & Rubin, B. P. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2497 · Cited by 27
Nanotechnology-Aided Advancement in Combating the Cancer Metastasis
Singh, A. K., Malviya, R., Prajapati, B. G., Singh, S. K., Yadav, D., & Kumar, A. (2023) · Pharmaceuticals · doi:10.3390/ph16060899 · Cited by 25
“After further therapy with an anti-PD-L1 antibody, both the primary breast tumour and the lung metastasis were entirely eradicated in the mice [70].”
Cengel, K. A., & McKenna, W. G. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.02.001 · Cited by 24
“Therefore, there has been conexperiments, oncogenic ras expression leads to tumor formation and some of these tumors display malignant and metastatic phenotypes [19–21].”
BackgroundLin, P.-Y., Peng, S.-J., Shen, C., Pasricha, P. J., & Tang, S. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00071.2016 · Cited by 23
“The acinar Kras mutation has been used in animal models to study the origin and progression of pancreatic ductal adenocarcinoma (1, 10, 20).”
BackgroundMethodp204 Protein Is a Novel Modulator of Ras Activity
Ding, B., & Lengyel, P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m709680200 · Cited by 24
Metadata
- Authors
- Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Abramson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-01-01
- Volume
- 17
- Issue
- 24
- Pages
- 3112-3126
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC305262
- OpenAlex
- W2126663928
- Cited by
- 1,033
- References
- 84
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 38 · 2023: 34 · 2022: 40 · 2021: 67 · 2020: 46 · 2019: 45 · 2018: 46 · 2017: 55 · 2016: 49 · 2015: 63 · 2014: 69 · 2013: 67 · 2012: 53
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Lustgarten Foundation
- Dana-Farber Cancer Institute
- Barr Foundation
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic ductal adenocarcinoma, KRAS G12D, Ink4a/Arf, tumor suppressor inactivation, pancreatic intraepithelial neoplasia, premalignant pancreatic lesions, metastasis, mouse tumor model, tumor progression, stromal cell proliferation
- MeSH terms
- Animals, Fibroblasts, Humans, Mice, Transgenic, Pancreatic Neoplasms, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Viral Proteins, Tumor Suppressor Protein p53, Mice, Knockout, Integrases, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Suppressor Protein p14ARF, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.